DMXAA accelerates orthodontic tooth movement in mice by driving macrophage-mediated Rab13-enriched EV release
Background
Orthodontic tooth movement (OTM) is a complex biological process involving controlled periodontal tissue remodeling and bone resorption. Current orthodontic treatments often require extended durations, prompting a search for safe and effective acceleration strategies. Existing methods can have side effects or limited efficacy. DMXAA (Vadimezan), an immune-modulating drug with a known safety profile from clinical trials, is being investigated for its ability to stimulate pro-inflammatory cytokines, which are crucial mediators in the immune-mediated bone remodeling essential for OTM.
Study Design
Researchers established a murine OTM model in C57BL/6 mice, applying orthodontic force and administering local subperiosteal injections of DMXAA. Tooth movement distance, alveolar bone volume fraction, and osteoclast parameters were precisely quantified using Micro-CT and histology. To elucidate the mechanism, RNA-sequencing was performed on bone marrow-derived macrophages (BMDMs), alongside sEV proteomics and functional osteoclastogenesis assays. Specificity was confirmed through macrophage depletion and Rab13 knockdown models, ensuring the observed effects were directly attributable to DMXAA's actions on macrophages and their secreted vesicles.
Results
Local DMXAA administration significantly enhanced orthodontic tooth movement and its rate in mice under orthodontic force. This acceleration was accompanied by reduced alveolar bone volume and increased osteoclast numbers on the compressive force side of the tooth. DMXAA treatment led to macrophage accumulation at the force-applied site, polarizing them towards M1-like pro-inflammatory phenotypes. These activated macrophages exhibited high secretion of chemokines CCL5 and CXCL10. Furthermore, small extracellular vesicles (sEVs) derived from DMXAA-treated macrophages were found to be enriched with Rab13 protein. > These Rab13-enriched sEVs directly contributed to osteoclast fusion and maturation, thereby playing a critical role in accelerating OTM.
Key Findings
- Local DMXAA administration significantly enhanced orthodontic tooth movement in mice.
- DMXAA treatment led to reduced alveolar bone volume and increased osteoclast numbers.
- DMXAA induced
M1-likemacrophage polarization and high secretion ofCCL5andCXCL10. - Small extracellular vesicles (sEVs) from DMXAA-treated macrophages were enriched with Rab13 protein.
Rab13-enriched sEVs contributed to osteoclast fusion and maturation, accelerating OTM.
Why It Matters
This study identifies DMXAA as a promising therapeutic agent for accelerating orthodontic tooth movement, potentially shortening treatment times for patients. The findings suggest a novel dual mechanism: DMXAA's ability to induce chemokine-driven osteoclast differentiation and its stimulation of Rab13-sEV-mediated osteoclast fusion. For clinicians and biohackers, this opens avenues for exploring immune-modulating compounds to optimize bone remodeling processes. The identification of the Rab13-sEV axis also provides a new target for future drug development, potentially leading to more precise and localized interventions to enhance orthodontic efficiency without systemic side effects. While preclinical, this work lays a foundation for translating DMXAA's benefits into a usable clinical protocol.
dmxaa
orthodontic-tooth-movement
bone-remodeling
macrophage-polarization
osteoclastogenesis
extracellular-vesicles